Electrochemotherapy in combination with chemoradiotherapy in the treatment of oral carcinomas in advanced stages of disease: efficacy, safety, and clinical outcomes in a small number of&amp;nbsp;selected cases

Domanico, Rossana; Trapasso, Serena; Santoro, M.; Pingitore, D.; Allegra, Eugenia

doi:10.2147/dddt.s75752

Cited by 13 publications

(22 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… Landstorm FJ et al, Acta Otolaryngol, 2015 [ 33 ] Prospective 18 Nd (100) Median 58 months BLM i.t. Domanico R et al, Drug Des Devel Ther, 2015 [ 34 ] Experimental 4 0 3 (75) 3 (75) 1 BLM i.v. Campana LG et al, EJSO, 2016 [ 18 ] Prospective multicenter 35 14 (40.7%) 21 (60) 30 (85.2) 1–12 (evaluation at 2 months) BLM i.v.&i.t., CDDP i.t.…”

Section: Discussionmentioning

confidence: 99%

Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis

et al. 2017

View full text Add to dashboard Cite

BackgroundExtensive squamous cell carcinoma has few therapeutic options. In such cases, electrochemotherapy involving electroporation combined with antineoplastic drug appears to be a new potential option and may be considered as an alternative treatment. The aim of this retrospective single-center study was to evaluate electrochemotherapy efficacy in treatment of locally advanced stage III squamous cell carcinoma, in which surgical procedures would have entailed wide tissue sacrifice.MethodsClinical features, treatment response, and adverse effects were evaluated in 22 patients treated with electrochemotherapy with intravenous injection of bleomycin for extensive stage III cutaneous squamous cell carcinoma. Treatment of cutaneous lesions were performed according to the European Standard Operating Procedures of Electrochemotherapy.ResultsOverall response to electrochemotherapy treatment was observed in 18 (81.8%) patients. Clinical response with necrosis of tumor mass was observed from the first session and lasted for all follow up period that ranged between 5 and 48 months with a median of 34 months. Overall the treatment was well tolerated with a very low complication rate.ConclusionsElectrochemotherapy represents a safe and effective therapeutic approach, associated with a good tolerability.

show abstract

Section: Discussionmentioning

confidence: 99%

Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Most publications reported on studies of prospective design, i.e., phase 2 observational studies [17][18][19][20]22,[24][25][26][27][29][30][31][33][34][35]; only three studies were retrospective [25][26][27], and one was a case report [36] (Table 1). Four studies were reported in more than one publication [15][16][17]21,23,25,28,29,32,33].…”

Section: Characteristics Of the Eligible Studiesmentioning

confidence: 99%

“…Four studies were reported in more than one publication [15][16][17]21,23,25,28,29,32,33]. Individual patient data were reported in 10 studies (86 patients, 52.4%) [17,18,20,[24][25][26]29,33,34,36] and group data in six studies (78 patients, 47.6%) [19,22,27,30,31,35]. The number of patients with mucosal HNC treated in these studies ranged from 1 to 43 patients (median 6.5; interquartile range 2.5-15.5).…”

Section: Characteristics Of the Eligible Studiesmentioning

confidence: 99%

Electrochemotherapy in Mucosal Cancer of the Head and Neck: A Systematic Review

Strojan

Groselj

Serša

et al. 2021

Cancers

View full text Add to dashboard Cite

Electrochemotherapy (ECT) is a local ablative treatment that is based on the reversible electroporation and intracellular accumulation of hydrophilic drug molecules, which greatly increases their cytotoxicity. In mucosal head and neck cancer (HNC), experience with ECT is limited due to the poor accessibility of tumors. In order to review the experience with ECT in mucosal HNC, we undertook a systematic review of the literature. In 22 articles, published between 1998 and 2020, 16 studies with 164 patients were described. Curative and palliative intent treatment were given to 36 (22%) and 128 patients (78%), respectively. The majority of tumors were squamous cell carcinomas (79.3%) and located in the oral cavity (62.8%). In the curative intent group, complete response after one ECT treatment was achieved in 80.5% of the patients, and in the palliative intent group, the objective (complete and partial) response rate was 73.1% (31.2% and 41.9%). No serious adverse events were reported during or soon after ECT and late effects were rare (19 events in 17 patients). The quality-of-life assessments did not show a significant deterioration at 12 months post-ECT. Provided these preliminary data are confirmed in randomized controlled trials, ECT may be an interesting treatment option in selected patients with HNC not amenable to standard local treatment.

show abstract

“…In contrast to radiotherapy, it is possible to repeat several ECT cycles without precluding other types of treatment on the same patient if new metastases develop. ECT has a favorable cost-effectiveness ratio with a cost of € 1,901.05 per achieved response in comparison with other techniques to control and treat cutaneous and subcutaneous melanomas [13, 19, 24, 33, 34].…”

Section: Advantage and Disadvantage Of Ectmentioning

confidence: 99%

“…It is applied for treating melanomas, sarcomas, and other types of skin cancer, cervix leiomyosarcoma, and breast cancer. Figure 1 shows the result of an actual treatment using ECT [2, 13–15].…”

Section: Introductionmentioning

confidence: 99%

Electrochemotherapy: A Review of Current Status, Alternative IGP Approaches, and Future Perspectives

Esmaeili

Friebe

2019

Journal of Healthcare Engineering

View full text Add to dashboard Cite

The efficiency of electroporation (EP) has made it a widely used therapeutic procedure to transfer cell killing substances effectively to the target site. A lot of researches are being done on EP-based cancer treatment techniques. Electrochemotherapy (ECT) is the first EP-based application in the field of drug administration. ECT is a local and nonthermal treatment of cancer that combines the use of a medical device with pharmaceutical agents to obtain local tumor control in solid cancers. It involves the application of eight, 100µs, pulses at 1 or 5000 Hz frequency and specified electric field (V/cm) with a median duration of 25 minutes. The efficacy of chemotherapeutic drugs increases by applying short and intense electrical pulses. Several clinical studies proposed ECT as a safe and complementary curative or palliative treatment option (curative intent of 50% to 63% in the treatment of Basal Cell Carcinoma (BCC)) to treat a number of solid tumors and skin malignancies, which are not suitable for conventional treatments. It is used currently for treatment of cutaneous and subcutaneous lesions, without consideration of their histology. On the contrary, it is also becoming a practical method for treatment of internal, deep-seated tumors and tissues. A review of this method, needed instruments, alternative image-guided procedures (IGP) approaches, and future perspectives and recommendations are discussed in this paper.

show abstract

Electrochemotherapy in combination with chemoradiotherapy in the treatment of oral carcinomas in advanced stages of disease: efficacy, safety, and clinical outcomes in a small number of selected cases

Cited by 13 publications

References 17 publications

Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis

Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis

Electrochemotherapy in Mucosal Cancer of the Head and Neck: A Systematic Review

Electrochemotherapy: A Review of Current Status, Alternative IGP Approaches, and Future Perspectives

Contact Info

Product

Resources

About